Trending Stock News

Smith Salley & Associates Has Increased Its Tjx Cos New (TJX) Position; AcelRx Pharmaceuticals, Inc. (ACRX) Covered By 5 Bulls

Smith Salley & Associates increased Tjx Cos Inc New (TJX) stake by 4.24% reported in 2017Q3 SEC filing. Smith Salley & Associates acquired 4,948 shares as Tjx Cos Inc New (TJX)’s stock declined 3.78%. The Smith Salley & Associates holds 121,708 shares with $8.97 million value, up from 116,760 last quarter. Tjx Cos Inc New now has $48.42 billion valuation. The stock decreased 0.01% or $0.01 during the last trading session, reaching $76.58. About 3.80 million shares traded. The TJX Companies, Inc. (NYSE:TJX) has declined 2.02% since January 18, 2017 and is downtrending. It has underperformed by 18.72% the S&P500.

Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 20 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, May 6 by Seaport Global. The company was maintained on Friday, August 25 by RBC Capital Markets. The company was downgraded on Friday, October 13 by Jefferies. As per Monday, October 5, the company rating was maintained by Roth Capital. TH Capital maintained the shares of ACRX in report on Monday, October 5 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $7 target in Tuesday, May 3 report. Piper Jaffray maintained AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rating on Thursday, October 12. Piper Jaffray has “Hold” rating and $2.0 target. H.C. Wainwright maintained AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Friday, August 4 with “Buy” rating. The company was maintained on Tuesday, July 25 by Piper Jaffray. Jefferies maintained AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Friday, July 14 with “Buy” rating. See AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) latest ratings:

14/11/2017 Broker: Jefferies Rating: Hold New Target: $2.0 Maintain
12/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $2.0 Maintain
13/10/2017 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
25/08/2017 Broker: RBC Capital Markets Rating: Buy New Target: $6.0 Maintain
04/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
02/08/2017 Broker: Roth Capital Rating: Buy New Target: $12.5000 Maintain
01/08/2017 Broker: Cowen & Co Rating: Hold Maintain
25/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $3.0000 Maintain

Since October 2, 2017, it had 0 insider buys, and 1 insider sale for $53,752 activity. Hamel Lawrence G sold $53,752 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Monday, October 2.

The stock decreased 1.20% or $0.03 during the last trading session, reaching $2.05. About 269,759 shares traded. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has declined 14.24% since January 18, 2017 and is downtrending. It has underperformed by 30.94% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $103.19 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Investors sentiment decreased to 0.7 in Q3 2017. Its down 0.05, from 0.75 in 2017Q2. It worsened, as 12 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 8 funds opened positions while 11 raised stakes. 6.65 million shares or 37.02% less from 10.56 million shares in 2017Q2 were reported. Palo Alto Invsts Ltd holds 1.03M shares. Goldman Sachs Gru reported 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Williams Jones And Limited Co reported 0% stake. Da Davidson And Communications invested 0.01% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Gru One Trading Lp reported 60,379 shares stake. Jane Street Group Incorporated Limited Liability Company invested in 0% or 11,642 shares. Deutsche Fincl Bank Ag reported 126,264 shares. Moreover, Vanguard Grp Inc Incorporated has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 1.38 million shares. Geode Capital Mngmt Ltd Liability Company has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Barclays Public Limited Liability Corporation holds 56,473 shares or 0% of its portfolio. New York-based Commercial Bank Of New York Mellon has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Cambridge Invest Research Advsr invested in 11,988 shares. Susquehanna Grp Limited Liability Partnership reported 226,288 shares or 0% of all its holdings. 32,318 are held by Royal Bancorporation Of Canada. Citadel Advsrs Lc holds 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 107,310 shares.

Since September 1, 2017, it had 0 buys, and 1 insider sale for $1.45 million activity. Another trade for 20,000 shares valued at $1.45 million was sold by Herrman Ernie.

Among 28 analysts covering The TJX Companies (NYSE:TJX), 24 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. The TJX Companies had 67 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 30 by RBC Capital Markets. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, May 17. The firm has “Buy” rating given on Tuesday, September 26 by BMO Capital Markets. As per Tuesday, August 15, the company rating was maintained by Jefferies. Cowen & Co maintained the stock with “Buy” rating in Tuesday, August 15 report. The rating was initiated by BB&T Capital with “Buy” on Thursday, December 17. The stock of The TJX Companies, Inc. (NYSE:TJX) has “Outperform” rating given on Thursday, February 25 by Wedbush. The firm has “Outperform” rating by Wolfe Research given on Thursday, February 25. The stock of The TJX Companies, Inc. (NYSE:TJX) earned “Buy” rating by Buckingham Research on Thursday, October 19. The stock of The TJX Companies, Inc. (NYSE:TJX) earned “Outperform” rating by Cowen & Co on Thursday, February 25.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.02, from 1.02 in 2017Q2. It worsened, as 59 investors sold TJX shares while 374 reduced holdings. 104 funds opened positions while 328 raised stakes. 550.02 million shares or 0.12% less from 550.70 million shares in 2017Q2 were reported. Automobile Association stated it has 0.09% of its portfolio in The TJX Companies, Inc. (NYSE:TJX). Mu Limited reported 58,970 shares. Stratos Wealth owns 10,729 shares for 0.04% of their portfolio. 122,071 are owned by Wallington Asset Management Limited Liability. Qs Invsts has 0.12% invested in The TJX Companies, Inc. (NYSE:TJX) for 200,808 shares. Credit Suisse Ag, a Switzerland-based fund reported 2.25 million shares. Cetera Advisor Networks Limited Co has invested 0.03% of its portfolio in The TJX Companies, Inc. (NYSE:TJX). Riverhead Cap Mgmt Limited Co invested 0.11% of its portfolio in The TJX Companies, Inc. (NYSE:TJX). Utah Retirement System holds 0.2% or 118,321 shares in its portfolio. Southeast Asset Inc has invested 0.11% in The TJX Companies, Inc. (NYSE:TJX). Nottingham Advsr Inc accumulated 12,112 shares. Franklin Resource accumulated 0.03% or 893,713 shares. Boston Common Asset Mngmt Limited holds 0.11% of its portfolio in The TJX Companies, Inc. (NYSE:TJX) for 12,170 shares. Pittenger And Anderson holds 89,853 shares or 0.6% of its portfolio. Sei Invs reported 251,744 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *